These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3016405)

  • 1. Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
    Stumpe KO; Overlack A; Kolloch R; Schatz J; Witte PU; Pahnke K
    Klin Wochenschr; 1986 Jun; 64(12):558-62. PubMed ID: 3016405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
    Böhm RO; van Baak MA; Rahn KH
    Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
    Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
    Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.
    Predel HG; Düsing R; Bäcker A; Kipnowski J; Kramer HJ
    Am J Cardiol; 1987 Apr; 59(10):143D-148D. PubMed ID: 3034023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
    Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
    Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and long-term effects of ramipril in hypertension.
    de Leeuw PW; Birkenhäger WH
    Am J Cardiol; 1987 Apr; 59(10):79D-82D. PubMed ID: 3034038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.
    Wenting GJ; Blankestijn PJ; Poldermans D; van Geelen J; Derkx FH; Man in't Veld AJ; Schalekamp MA
    Am J Cardiol; 1987 Apr; 59(10):92D-97D. PubMed ID: 3034041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.
    Mroczek WJ
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S147-9. PubMed ID: 1725028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.
    Kaneko Y; Omae T; Yoshinaga K; Iimura O; Inagaki Y; Ishii M; Saruta T; Yamada K; Kumahara Y; Ito K
    Am J Cardiol; 1987 Apr; 59(10):86D-91D. PubMed ID: 3034040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ramipril on 24-hour variability of blood pressure and heart rate in essential hypertension.
    Tochikubo O; Asahina S; Kaneko Y
    Am J Cardiol; 1987 Apr; 59(10):83D-85D. PubMed ID: 3034039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.
    Becker RH; Baldes L; Treudler M
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S35-9. PubMed ID: 2474099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension.
    Witte PU; Walter U
    Am J Cardiol; 1987 Apr; 59(10):115D-120D. PubMed ID: 3034018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.
    de Leeuw PW; Lugtenburg PL; van Houten H; Looman JH; Birkenhäger WH
    J Cardiovasc Pharmacol; 1985; 7(6):1161-5. PubMed ID: 2418304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of ramipril.
    Ball SG; Robertson JI
    Am J Cardiol; 1987 Apr; 59(10):23D-27D. PubMed ID: 3034028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
    Iimura O; Shimamoto K
    Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo.
    Villamil AS; Cairns V; Witte PU; Bertolasi CA
    Am J Cardiol; 1987 Apr; 59(10):110D-114D. PubMed ID: 3034017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ramipril on ambulatory blood pressure: a multicenter trial.
    Burris JF
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S131-3. PubMed ID: 1725022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.
    Vasmant D; Bender N
    J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S46-52. PubMed ID: 2483429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ramipril on arterial hemodynamics.
    Benetos A; Vasmant D; Thiéry P; Safar M
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S153-6. PubMed ID: 1725030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
    Bauer B; Lorenz H; Zahlten R
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S70-4. PubMed ID: 2474109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.